Welcome to our dedicated page for Lifecore Biomedical news (Ticker: LFCR), a resource for investors and traders seeking the latest updates and insights on Lifecore Biomedical stock.
Lifecore Biomedical, Inc. (LFCR) reports developments as a fully integrated injectables CDMO focused on sterile pharmaceutical products. The company provides development, fill and finish services for syringes, vials and cartridges, including complex formulations, and manufactures injectable-grade hyaluronic acid for biopharmaceutical and biotechnology customers.
Company news commonly covers financial results, revenue and Adjusted EBITDA guidance, commercial site transfer programs, technical transfer and PPQ work, new CDMO manufacturing service agreements, customer program expansions, cost-containment initiatives, biomanufacturing conference participation and Nasdaq inducement equity grants.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Lifecore Biomedical (NASDAQ: LFCR) announced on April 14, 2023, that it received a notice from Nasdaq regarding non-compliance with Listing Rule 5250(c)(1) due to the delayed filing of its Quarterly Report on Form 10-Q for the period ended February 26, 2023. While the notice does not immediately affect the listing or trading of LFCR's securities, the Company has 60 days to submit a compliance plan, with a possible extension of 180 days to file the Form 10-Q if the plan is accepted. Lifecore is actively working to complete the filing to restore compliance and has emphasized its commitment to addressing the situation promptly.
Lifecore Biomedical has announced the successful sale of its O Olive Oil and Vinegar business for $6.23 million, marking the completion of its monetization of remaining Curation Foods assets. The deal includes $3.12 million in cash and a $3.12 million seller's note maturing on March 31, 2026, accruing 12% interest. The O Olive business generated $9.2 million in revenue over the trailing twelve months ending November 27, 2022. Proceeds from the sale will be used to repay existing borrowings under credit facilities, and results from O Olive will be reported as discontinued operations starting fiscal Q4 2023. CEO James G. Hall emphasized the company's focus on long-term growth strategies to meet customer demand.
Lifecore Biomedical has announced a new term sheet to expand its relationship with a long-term customer in the Hyaluronic Acid sector. The agreement includes a non-refundable cash commitment of $10 million from the customer, divided into installments over seven months, to enhance Lifecore's infrastructure and manufacturing capacity. Additionally, the customer aims to reimburse Lifecore up to $15 million for capital expenditures related to this expansion. This could lead to a multi-year amendment of the existing contract manufacturing agreement, enhancing Lifecore's operational capabilities and financial efficiency.
Lifecore Biomedical, based in Chaska, Minnesota, announced on March 16, 2023, that its Board of Directors will evaluate strategic alternatives to maximize shareholder value. These alternatives could include a potential sale of the Company and financing transactions. Morgan Stanley has been appointed as the financial advisor, and Latham & Watkins as legal counsel. The strategic review will begin once Lifecore secures a forbearance agreement from its lenders. CEO James G. Hall emphasized the company’s commitment to its customers and employees and highlighted the growing demand for specialized contract development and manufacturing services.
Lifecore Biomedical announced its intention to explore strategic alternatives, including a potential sale, to maximize shareholder value. The company reported fiscal second quarter 2023 results showing consolidated revenues of $38.8 million, down 10.7% year-over-year, and a consolidated net loss of $12.4 million. Gross profit decreased by 51.7% to $7.1 million. Lifecore's development pipeline expanded to 25 active projects, and it entered a term sheet to expand its relationship with a key customer, involving substantial upfront payments. The company has withdrawn its fiscal 2023 guidance due to the strategic review.